Moderna strengthens mRNA manufacturing with OriCiro buyout
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) has agreed to acquire OriCiro Genomics K.K., a Tokyo-based company focused on cell-free synthesis and amplification of plasmid DNAs to consolidate its mRNA manufacturing capabilities, the companies announced Wednesday.
Per the terms of the agreement, Moderna (MRNA), a leading mRNA-based COVID-19 vaccine maker, will acquire OriCiro for $85M.

"With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing," Moderna's (MRNA) Chief Executive StÃ©phane Bancel said.
"I am confident that our technology and talent will be a highly strategic fit with Moderna," said Nasir Kato Bashiruddin, CEO of OriCiro, remarked.

Thanks to its blockbuster COVID-19 vaccine, Moderna (MRNA) has consolidated its deal-making prowess reporting more than $8.3B in cash and short-term investments as of the end of Q3 2022.